• Jorge F Máspero, Claudio A Parisi, Mónica De Gennaro, Osvaldo Benhabib, and Marta Lampert.
• Alergia Infantil, Hospital Alemán.
• Arch Argent Pediatr. 2009 Oct 1;107(5):452-6.

UnlabelledWe report the case of a child with diagnosis of chronic urticaria/angioedema and its evolution upon omalizumab treatment.Case ReportOur patient is a 12-years-old female who suffered for 14 months severe chronic urticaria/angioedema. She had a poor response to the highest doses of combined therapy with 3 antihistamines, steroids and anti-leukotrienes and great impairment of her quality of life. An autologous serum skin test was positive until 1:100 dilutions, leading to the diagnosis of chronic autoimmune urticaria. Due to the lack of response to treatment, therapy with omalizumab was administered. A notable reduction in symptoms toward the third dose was observed. After 12 months of this treatment, the patient is asymptomatic and has a negative autologous serum test.ConclusionOmalizumab could be a therapeutic option for patients with autoimmune urticaria unresponsive to other treatments.

18 keywords...

hide…